TransMedics Group, Inc. $TMDX Shares Sold by LPL Financial LLC

Key Points

• LPL Financial LLC has reduced its holdings in TransMedics Group, Inc. by 25.9%, selling 6,841 shares and now owns 19,545 shares valued at approximately $1.31 million.
• During the first quarter, various hedge funds significantly increased their positions in TransMedics, with GAMMA Investing LLC boosting its holdings by 551.7%.
• Analysts have upgraded the stock's ratings, with Piper Sandler raising the target price from $125 to $145 and an overall consensus rating of "Moderate Buy" on the stock.

LPL Financial LLC reduced its holdings in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 25.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,545 shares of the company's stock after selling 6,841 shares during the period. LPL Financial LLC owned approximately 0.06% of TransMedics Group worth $1,315,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of the business. NBC Securities Inc. purchased a new position in TransMedics Group in the 1st quarter worth approximately $25,000. Hager Investment Management Services LLC lifted its position in TransMedics Group by 38.3% during the first quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock worth $50,000 after buying an additional 205 shares in the last quarter. CWM LLC lifted its position in TransMedics Group by 20.1% during the first quarter. CWM LLC now owns 925 shares of the company's stock worth $62,000 after buying an additional 155 shares in the last quarter. GAMMA Investing LLC boosted its stake in TransMedics Group by 551.7% during the first quarter. GAMMA Investing LLC now owns 1,564 shares of the company's stock worth $105,000 after buying an additional 1,324 shares during the last quarter. Finally, Sava Infond d.o.o. grew its holdings in TransMedics Group by 46.7% in the 1st quarter. Sava Infond d.o.o. now owns 2,200 shares of the company's stock valued at $148,000 after buying an additional 700 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Analysts Set New Price Targets

TMDX has been the topic of several analyst reports. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a report on Monday. Morgan Stanley upped their price objective on shares of TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a report on Friday, August 1st. Wall Street Zen raised shares of TransMedics Group from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Canaccord Genuity Group boosted their target price on shares of TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a report on Tuesday, July 15th. Finally, Oppenheimer raised their price target on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a report on Tuesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $123.00.

Insider Buying and Selling at TransMedics Group

In other news, Director Edward M. Basile sold 5,000 shares of TransMedics Group stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $126.45, for a total value of $632,250.00. Following the completion of the transaction, the director owned 2,866 shares in the company, valued at approximately $362,405.70. This trade represents a 63.56% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Anil P. Ranganath sold 686 shares of the business's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $139.80, for a total value of $95,902.80. Following the transaction, the insider directly owned 13,955 shares of the company's stock, valued at approximately $1,950,909. This represents a 4.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.00% of the company's stock.

TransMedics Group Trading Down 4.1%

NASDAQ TMDX traded down $4.88 on Monday, reaching $114.97. The stock had a trading volume of 904,946 shares, compared to its average volume of 1,260,528. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61. The stock has a fifty day moving average price of $121.11 and a two-hundred day moving average price of $102.00. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.00. The firm has a market capitalization of $3.92 billion, a price-to-earnings ratio of 62.10 and a beta of 2.09.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The business had revenue of $157.37 million during the quarter, compared to analysts' expectations of $146.64 million. During the same period in the previous year, the firm posted $0.35 earnings per share. The company's revenue was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.